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Leprosy is a chronic infectious disease caused by Mycobacterium
leprae. Leprosy patients present with a spectrum of clinical
disease that depends on the ability of the host to make a cellular
immune response to the bacterium [1]. At one pole of the spec-
trum is tuberculoid leprosy (TT), which is associated with strong
cell mediated immunity (CMI) and delayed type hypersensitivity
(DTH) responses to M. leprae. In contrast, at the other end of the
disease spectrum is lepromatous leprosy (LL) where the disease
is disseminated throughout the body.
Leprosy is still considered a public health problem in 32 coun-
tries; however, 16 of these from the African, Asian and South
American continents are responsible for 92% of all registered
patients [2]. Leprosy cases are distributed globally unevenly. The
application of multi-drug therapy (MDT) has changed the picture
of leprosy, with the numbers of registered cases worldwide falling
from 1·3 million in 1995 to 641091 in 2000 [3,4]. Despite these sta-
tistics leprosy still poses some challenges. The biggest challenge
for achieving elimination is the fact that even though the preva-
lence of leprosy is decreasing the same is not true for incidence,
which has remained the same [5]. In addition, because of the long
incubation period before the disease appears, many more new
leprosy patients will continue to emerge in endemic countries for
many years.
What makes the control of leprosy difﬁcult is that no speciﬁc
and reliable immunological tool is available to be used for detec-
tion of M. leprae exposure. A diagnostic reagent, which would be
analogous to, but more speciﬁc than the Mantoux skin test used
for detecting exposure to M. tuberculosis, is required. Although
the Mantoux test can be positive following exposure to non-
tuberculous mycobacteria, individuals with skin test indurations
greater than 10 or 15mm are at higher risk of developing tuber-
culosis. Such individuals can then be referred for a chest X-ray
and clinical examination to conﬁrm or exclude tuberculosis. If
such a test were to be developed for leprosy it would aid in the
understanding of immune responses in healthy M. leprae-exposed
individuals and those who are subclinically infected. Such a test
may also be able to identify areas with greater leprosy endemic-
ity within a country.
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SUMMARY
In order to identify T cell epitopes within the Mycobacterium leprae 45-kD serine-rich antigen, we
analysed responses to overlapping 17-mer peptides encompassing the whole antigen in non-exposed
UK controls, Pakistani leprosy patients and tuberculosis patients in both the United Kingdom and 
Pakistan. This antigen has been described as M. leprae-speciﬁc, although it has a hypothetical homo-
logue in M. tuberculosis. Human peripheral blood mononuclear cells were stimulated with peptide for
5 days and IFN-g measured in supernatants by ELISA. Some peptides were recognized more frequently
by T cells from tuberculoid leprosy patients than those from UK controls, suggesting that such T cell
epitopes might have diagnostic potential, while other peptides induced greater responses among UK
control subjects. Short-term cell lines conﬁrmed that these assays detected speciﬁc T cell recognition
of these peptides. However, many tuberculosis patients also recognized these potentially speciﬁc pep-
tides suggesting that there could be a true homologue present in M. tuberculosis.
Keywords cell mediated immunity (CMI) diagnosis interferon-gamma (IFN-g) M. leprae
peptides 
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Skin tests using Lepromin and Leprosin have been used,
which are prepared from whole autoclaved M. leprae and soluble
antigens from fractionated M. leprae, respectively. Lepromin is a
biphasic test developed by Mitsuda called the Fernandez reaction
[6] with reactions read after 48–72h and also read at 4weeks, the
Mitsuda reaction. Lepromin and Leprosin are not diagnostic
reagents for leprosy because they lack the required speciﬁcity 
and have been shown to induce positive skin test reactions in 
the majority of healthy endemic and non-endemic controls. The
Lepromin test is better used for classifying leprosy patients across
the spectrum of disease.
In order to develop a speciﬁc immunological tool for the
purpose of diagnosing M. leprae exposure, one approach is to
identify T cell epitopes within an antigen that are recognized
speciﬁcally by individuals exposed to M. leprae and not other
mycobacteria. A number of antigens have been identiﬁed that
induce T cell responses from tuberculoid patients and leprosy
patient contacts in vitro: for example, the 70-kD, 65-kD, 35-kD,
30/31-kD, 18-kD and 10-kD antigens [7–12]. However, the major-
ity of these antigens induce cross-reactive immune responses 
as there are homologues present in other mycobacterial species 
[13]. Previous studies using M. leprae fractionated antigens 
on nitrocellulose indicated that many additional proteins might
be recognized as antigens [14–17]; however, there are problems
with the speciﬁcity issue when considering such fractions as 
antigens.
A number of other studies have demonstrated the usefulness
of in vitro assays for T cell proliferation or IFN-g secretion as 
good correlates of skin test responsiveness in humans [18] [19].
To our knowledge, no M. leprae peptides to date have been used 
as diagnostic reagents in humans under in vivo conditions,
although it should be possible to elicit DTH responses to such
peptides in man, as shown for two human immunodeﬁciency 
virus peptides in a study on human volunteers [20]. Previous
studies have demonstrated skin test responses to peptides of 
M. tuberculosis 19-kD in mice [21] or M. leprae 65-kD, 28-kD, 
18-kD peptides in guinea pigs [22] and M. tuberculosis and M.
intracellulare 19-kD peptides in guinea pigs [23]. Recently a 
study on bovine tuberculosis demonstrated the importance of
antigen-speciﬁc cytokine readout systems for the early identiﬁ-
cation of M. bovis infection in cattle and stressed the potential 
of using antigen cocktails for immunodiagnosis [24]. Another
study [25] has demonstrated the usefulness of peptide mixtures
from ESAT-6 and CFP-10 as potential diagnostic reagents for
tuberculosis.
In this study, IFN-g production in response to PPD, M. leprae
sonicate, the 45-kD antigen and 45-kD peptides was used to
measure the cellular immunity of healthy, non-exposed UK con-
trols and tuberculoid leprosy patients. The gene encoding the M.
leprae 45-kD antigen was identiﬁed originally in a lambda gt 11
library [26,27]. Sera from tuberculoid and lepromatous leprosy
patients contained antibodies reactive to the 45-kD fusion
protein, but no responses were detected in sera from endemic
controls or tuberculosis patients [27]. In a study in Mexico the 
45-kD antigen was recognized more strongly by PBMCs from
tuberculoid leprosy patients and leprosy contacts than by endemic
controls, and was not recognized by T cells from tuberculosis
patients [28]. This suggested that the 45-kD antigen might be spe-
ciﬁc for M. leprae.
Our study involved using individual peptides encompassing
the entire 45-kD antigen in a standard in vitro PBMC assay in
order to measure IFN-g, which is an important cytokine in the
protective immune response against M. leprae. Skin lesions from
tuberculoid leprosy patients contain the type 1 cytokine IFN-g
mRNA, which is not found in lesions from lepromatous leprosy
patients [29]. Lepromatous leprosy patients were not included in
this study as they are unable to make M. leprae-speciﬁc immune
responses resulting in the uncontrolled growth of the organism in
vivo [30,31]; however, they produce immune responses to cross-
reactive antigens such as PPD. In a study by Kaplan et al. 
bacterial loads were reduced signiﬁcantly within the lesions of
lepromatous leprosy patients when injected with recombinant
IFN-g [32]. The aim of our study was to identify immunodomi-
nant T cell determinants within the 45-kD antigen and to assess
if there were differences in the IFN-g responses from peripheral
blood mononuclear cells of tuberculoid leprosy patients, healthy
UK controls and tuberculosis patients to the peptides. Our study
excluded LL leprosy patients, as they have depressed type 1
immune responses and defective CMI. In initial studies, all the
peptides encompassing the 45-kD antigen were tested; further
experiments involved testing a few peptides in additional UK 
controls and leprosy patients and tuberculosis patients from the
endemic country to evaluate speciﬁcity. Multi-drug therapy has
been highly successful in the treatment of leprosy; however, the
identiﬁcation of T cell epitopes that are speciﬁc to M. leprae could
still prove of major importance in the context of identifying
people who are exposed and possibly subclinically infected with
M. leprae.
MATERIALS AND METHODS
Patients and controls
In the United Kingdom, 40 heparinized buffy coat blood bank
samples (North London Blood Transfusion Service, Colindale,
UK and South London Blood Transfusion Service, Tooting, UK)
were used as a source of PBMC from leprosy-unexposed individ-
uals. As the blood bank will not accept blood donations from 
volunteers who may have lived or spent long periods in the
tropics, the blood used was derived from individuals who would
not have been exposed to M. leprae. Blood samples from six 
pulmonary tuberculosis patients in the United Kingdom were
obtained with informed consent, recruited at the Homerton 
Hospital, London. All patients were on antituberculosis therapy
and only two were of Caucasian origin, the rest were from Africa
or Indian subcontinent.
In Pakistan, blood samples were obtained with informed
consent from 31 paucibacillary leprosy patients (polar tubercu-
loid/borderline tuberculoid TT/BT). The leprosy patients were all
of Pakistani ethnic origin and recruited at the Marie Adelaide
Leprosy Centre, Karachi, Pakistan. Patients were diagnosed and
classiﬁed by standard clinical and bacteriological parameters and
all had BCG scars. All the patients were in the early stages of
multi drug therapy (less than 4weeks’ treatment) and none had
a previous history of tuberculosis or other diseases. Sixteen pul-
monary tuberculosis patients were recruited at Masoomeen Hos-
pital, Karachi; these patients were on standard antituberculosis
treatment.
Reagents
Sixty-seven 17-mer synthetic peptides spanning the sequence of
the M. leprae 45kD antigen, overlapping by 10 amino acids, were
synthesized with long-chain biotin linked to the peptide by a
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spacer. The synthetic peptides were synthesized using Fmoc
chemistry methodology and their purity was conﬁrmed by
reverse-phase HPLC. A selection of the peptides were screened
for endotoxin contamination; endotoxin contamination was
0·08–0·4 endotoxin unit per ml (EU/ml), giving a ﬁnal con-
centration in the assays of 0·008–0·04EU/ml. There was no 
correlation between the frequency of responders to peptides 
with 0·04EU/ml or 0·008EU/ml of endotoxin. The programs 
FINDPATTERNS and  SYFPEITHI were used to predict the 
presence of HLA-DR binding motifs in the peptide sequences
(http://134·2.96·221/Scripts/MHCServer.dLl/EpPredict.htm). In
the United Kingdom, 67 overlapping peptides were used to test
for T cell responses. In Karachi, because of the smaller volumes
of blood available from patients, 40 peptides were tested initially
(every second peptide out of the total 67, but still encompassing
the whole 45-kD antigen) and then three peptides tested in 
subsequent experiments. The peptides were used at a ﬁnal con-
centration of 10mg/ml. The amino acid sequence of the 45kD
antigen is found on the SWISSPROT database using the acces-
sion number Q07297. M. leprae 45-kD was synthesized in Leiden
by subcloning the gene into a pTrcHisB vector. The expressed
protein was puriﬁed under denaturing conditions using a nickel
chelate afﬁnity resin and the puriﬁed protein fractions were
analysed against PBS [28]. The purity of M. leprae 45-kD was 
conﬁrmed by Coomassie blue-stained SDS-PAGE and visible
contamination of Escherichia coli proteins was excluded by
immunoblotting using a peroxidase-labelled rabbit anti-E. coli
antiserum [28]. M. leprae sonicate (batch no. CD212) was
obtained from Dr R. Rees, National Institute for Medical
Research, Mill Hill, UK and used at a ﬁnal concentration of 
10mg/ml. Phytohaemagglutinin (PHA; Difco Laboratories, West
Mosley, UK) was used at a ﬁnal concentration of 5mg/ml as a 
positive control. M. tuberculosis protein puriﬁed derivative 
(PPD; batch no. RT 49, Statens SerumInstitut, Copenhagen,
Denmark) was used at a ﬁnal concentration of 10mg/ml.
Isolation of PBMC from whole blood, lymphocyte
transformation assays and cytokine assays
These were standard procedures as described in our previous
study [33].
Positive control samples were included on each ELISA plate;
these were pooled supernatants from PHA-stimulated cultures,
which had been aliquoted and frozen until the day of the ELISA.
Test samples from negative control cultures were below the 
detection limit of the ELISA and so subtraction of background
cytokine measurement from test wells was not necessary. The
mitogen PHA was used as a positive control: all the subjects were
responders (IFN-g production ≥100pg/ml) to PHA.
Short-term cell lines
PBMCs obtained from normal healthy donors were isolated from
heparinized venous blood by density-gradient sedimentation over
Ficoll as described above. Adherent cells (AC) were cultured over
14 days and non-adherent cells (NAC) were stimulated with
peptide p45 at 1mg/ml for 1 h and then plated out in wells at 2 ¥
10
5 PBMCs/well. The PBMCs were fed every 3 or 4 days with 10%
Lymphocult T (Biotest, Solihull, UK) and growth medium. After
2 weeks’ short-term cell lines were added to washed monocyte-
derived macrophages (APCs) not presenting any peptide or
antigen (negative control), onto monocytes pulsed with peptide
p45 at a ﬁnal concentration of 10 mg/ml or placed onto monocytes
pulsed with peptide p18 (from the amino terminal of the 45-kD
antigen). All the cell lines were stimulated for 2–3 days at 37°C
in a humidiﬁed incubator. Supernatants were removed before cell
harvest for ﬂow cytometry and stored at –20°C for subsequent
ELISA testing.
Monoclonal antibodies
Antibodies to CD3 ﬂuorescein isothiocyanate (FITC), CD25 phy-
coerythrin (PE) were purchased from Becton Dickinson, Cowley,
Oxford, UK. Mouse IgG1 isotype control FITC and mouse IgG1
isotype control PE were purchased from Pharmingen (obtained
through Becton Dickinson, Cowley, Oxford, UK).
HLA typing
Low resolution HLA typing of UK controls and Pakistani leprosy
and tuberculosis patients was performed at the Hammersmith
Hospital, Hammersmith, UK using PCR.
Criteria for threshold cut-offs
Threshold cut-offs were used to determine positive and negative
responses in lymphocyte stimulation assays. Analysis of the data
from unstimulated PBMC cultures of UK controls and leprosy
patients showed that no IFN-g was detected in these control wells
(below the ELISA detection limit, 50pg/ml). Therefore, there was
no need to subtract any background IFN-g. A value of IFN-g
greater than or equal to 100pg/ml (≥100pg/ml), double the 
detection limit of the assay was deﬁned as a positive IFN-g
response.
Statistical analysis
A non-parametric test (Wilcoxon rank sum test, P) was used to
evaluate the statistical signiﬁcance for comparison of peptide
responses between healthy UK donors and tuberculoid (TT/BT)
leprosy patients in Pakistan. This was performed using the
STATA 6 program and values of P < 0·05 were considered to be
signiﬁcant.
RESULTS
Response to mycobacterial antigens in the study subjects
PBMC cultures from 20 UK non-exposed controls and 
15 polar/borderline tuberculoid leprosy patients were stimulated
with PHA, PPD, M. leprae sonicate and M. leprae 45-kD antigen
for 5 days and IFN-g  measured in the culture supernatants 
by ELISA. The scatter plot in Fig. 1 illustrates the responses 
from individuals in both groups. Both groups responded 
strongly to PHA and M. tuberculosis PPD. Using production of
IFN-g  (100pg/ml to deﬁne a positive response, 87% leprosy
patients responded to M. leprae sonicate, more strongly than the
UK donors as expected (20% responders) (mean 1260pg/ml,
median 700pg/ml, range 0–6950pg/ml and mean 98pg/ml, median 
0pg/ml, range 0–850pg/ml, respectively). Both groups of donors
showed very similar recognition of the 45-kD antigen 
(87% responders, mean 3190pg/ml, median 1300pg/ml, range
0–13500pg/ml; 85% responders, mean 2465pg/ml, median 
800pg/ml, range 0–14700pg/ml, respectively). As most UK con-
trols responded to M. tuberculosis PPD it is possible that the
responses observed to M. leprae 45-kD antigen could be a result
of prior mycobacterial exposure due to BCG vaccination. All 
subjects responded to the mitogen PHA.
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IFN-g production in response to 45kD peptides by 
UK controls
PBMC from the UK non-exposed subjects were tested against 67
synthetic peptides spanning the sequence of the M. leprae 45-kD
antigen. Certain immunodominant peptides induced frequent
responses in the UK controls (Table 1). M. leprae 45-kD peptide
sequences were compared to homologous M. tuberculosis pre-
dicted proteins using BLASTP on the Sanger Centre database.
Sequences were selected based on those that had highest 
scoring segment pairs (P-values indicating the signiﬁcance of
homology). Peptides p4 and p21 had relatively few amino acid 
mismatches with the equivalent M. tuberculosis sequence (6/17,
5/17, respectively), compared to peptides p12, p23, p32, p33, p34
and p45 which had 9/17, 9/17, 11/17, 10/17, 15/17 and 10/17 amino
acid mismatches, respectively (see Table 2a). Peptides p4, p32 
and p45 were recognized signiﬁcantly more strongly by the UK
controls (P < 0·006, P < 0·003, P < 0·011, respectively) than by
leprosy patients in Pakistan. This suggests that these peptides 
are not M. leprae speciﬁc but are cross-reactive with sequences
from a homologous antigen to which UK subjects have been
exposed.
Recognition of M. leprae 45-kD peptides by tuberculoid
leprosy patients
PBMC from leprosy patients were tested with 40 synthetic 
peptides spanning the entire 45-kD antigen. Some peptides were
recognized preferentially by T cells from the leprosy patients
rather than by UK controls, as shown in Table 1, which shows the
percentage of responders in the IFN-g assay to these peptides.
Amino acid comparisons of the immunodominant M. leprae
45-kD antigen peptides to the equivalent predicted amino acid
sequences of M. tuberculosis are shown in Table 2b. As can be
seen from the amino acid comparisons between the two species,
peptides p10 and p29 both have 11/17 amino acid mismatches with
M. tuberculosis but of these, only peptide p10 seems to show
slightly more recognition by leprosy patients than UK controls
but this is not signiﬁcant (P <  0·0976) as shown in Table 2b. 
Peptides p6, p18 and p20 have slightly fewer amino acid mis-
matches to the corresponding M. tuberculosis sequences (8/17,
10/17 and 6/17 mismatches, respectively). Despite peptide p20
having only 6/17 mismatches (at positions 1, 2, 3, 5, 6 and 16) it is
still a prominently recognized peptide within tuberculoid leprosy
patients, with greater recognition than in the UK controls (40%
and 10% responders, respectively, P < 0·0030) (Table 1). Peptide
p18 was also more often recognized signiﬁcantly by the leprosy
patients (P < 0·066); however, the value is not within the signiﬁ-
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Fig.1. IFN-g  responses induced by UK controls and TT/BT leprosy
patients to M. tuberculosis PPD, M. leprae sonicate (Mlson) and 45-kD
antigen in the initial testing. PBMCs were stimulated for 5 days and IFN-
g was measured in the culture supernatants by ELISA. Concentrations of
≥100pg/ml of IFN-g (twice the detection limit of the ELISA) were used to
deﬁne a positive response as shown by the line. N = 20 for UK controls
and n = 15 for TT/BT leprosy patients.
Table1. A comparison of responses between tuberculoid leprosy patients
and UK controls to peptides from the M. leprae 45-kD antigen in the
initial testing
% responders
TT/BT leprosy UK controls
Peptides (n = 15) (n = 20) P
p4† 0% 35% 0·006
p12 0% 25% 0·151
p21 27% 35% 0·951
p23 7% 20% 0·307
p32† 0% 45% 0·003
p33 13% 35% 0·074
p34 13% 30% 0·435
p45† 20% 65% 0·011
p6 13% 5% 0·395
p10 13% 0% 0·097
p18* 13% 5% 0·066
p20* 40% 10% 0·003
p29 7% 20% 0·769
PBMCs from tuberculoid (TT/BT) leprosy patients and UK controls
were stimulated with peptides and IFN-g  measured in supernatants col-
lected at 5days. Peptides p6–p29 were recognized more strongly (higher
IFN-g production) by T cells from the tuberculoid leprosy patients than
the UK controls. A non-parametric test (Wilcoxon rank sum test) was used
to evaluate the statistical signiﬁcance for comparison of peptide responses
between tuberculoid leprosy patients in Pakistan and UK controls (signif-
icance deﬁned as P < 0·05). †Peptides recognized to a signiﬁcantly greater
extent by the UK controls than the tuberculoid leprosy patients. Peptides
p4–p45 were recognized more strongly (higher IFN-g production) by T
cells from the UK controls than the tuberculoid leprosy patients. *Peptides
recognized to a signiﬁcantly greater extent by the TT/BT leprosy patients
than the UK controls.144 S. Brahmbhatt et al.
© 2002 Blackwell Science Ltd, Clinical and Experimental Immunology, 128:140–148
cance criteria (i.e. P < 0·05). In subsequent testing peptide p19,
which overlaps both the p18 and p20 sequences, was also included
in the testing in order to localize the epitopes recognized more
precisely.
Generation of peptide-speciﬁc short-term cell lines
To conﬁrm that subjects were making antigen-speciﬁc T cell
responses to the peptide, CD3
+ T cell lines (45K-1, 45K-2) were
derived from two UK controls whose PBMC proliferated in
response to a cross-reactive peptide from M. leprae 45-kD antigen
(peptide p45) (data not shown). Activation of CD3
+ T cells in the
45K-1 short-term T cell line following peptide restimulation was
measured by CD25 expression (a marker for IL-2Ra chain), indi-
cating that peptide p45 was being recognized by antigen-speciﬁc
T cells (more than half the CD3
+ T cells were activated, 55%). By
comparison a short-term cell line without any stimulation,
resulted in the loss of total CD3
+ T cells (66% compared to 86%
in stimulated cell line); this could be attributed to cells dying
Table2. Amino acid sequence comparisons between Mycobacterium leprae 45-kD peptides and homologueues in M. tuberculosis:
P
(a) Peptides recognized more strongly by UK controls than by leprosy patients
Peptide p4†
M. leprae 45-kD GPGSTPLWGAAEAWISL 0·074
M. tuberculosis Rv2892c (PPE) GPGSGPMMAAAAAWDSL
Peptide p12
M. leprae 45-kD ASRVSTF VAWLD GNAEN 0·94
M tuberculosis Rv0611c (hypothetical protein MW13621) ASRQSSMVS WNHGAAGW
Peptide p21
M. leprae 45-kD LKAINWFGQVSTTVAAL 0·0047
M. tuberculosis Rv2108 (PPE) LKAINWFGQFSTRIADK
Peptide p23
M. leprae 45-kD TVAALEADYDL MWVQNS 0·36
M. tuberculosis Rv2108 (PPE) RIAD KEADYEQMWFQDA
Peptide p32†
M. leprae 45-kD VNSFDSSSSSDSLYESI 0·999
M. tuberculosis Rv3597c (lsr2) VDDFDGSGAADETVEFG
Peptide p33
M. leprae 45-kD SSSSDSLYESIDNLYDS 0·87
M. tuberculosis Rv0027 (hypothetical protein MW 1191) PSSHDAIRESLDSLGPI
Peptide p34
M. leprae 45-kD LYESIDNLYDSVAQSEE 0·81
M. tuberculosis Rv3073c (hypothetical protein MW 13751) QEELHDSAALAELRKLT
Peptide p45†
M. leprae 45-kD LDSI I SSASASLLTTNS 0·992
M. tuberculosis Rv0164 (hypothetical protein MW20166) LFSVVATGAASLLT
(b) Peptides recognized more strongly by leprosy patients than by UK controls
Peptide p6
M. leprae 45kD AWISLAEQLMEAAQEVS 0·18
M. tuberculosis Rv3746c (PE) AWVSLSSLLPAGAEEVS
Peptide p10
M. leprae 45kD PASFAGETSDMLASRVS 0·992
M. tuberculosis Rv2829c (hypothetical protein MW 14611) PS SFPGDPADRLIYATA
Peptide p18*
M. leprae 45kD AGMVPLLTVLGNIIHTM 0·995
M. tuberculosis Rv2466c (hypothetical protein MW 23036) KVLDPLYTAMGNRIHNQ
Peptide p20*
M. leprae 45kD I I HTMALKAINWFGQVS 0·013
M. tuberculosis Rv2108 (PPE) RVQTTVLKAINWFGQFS
Peptide p29
M. leprae 45kD FEPAPQLV SRYCMDRRD 0·83
M. tuberculosis Rv0847 (lpqS) VRTGQDLL T RF CL ARR-
Peptides p4, p12, p21, p23, p32, p33, p34 and p45 have 6, 9, 5, 9, 11, 10, 15, and 10, respectively, out of 17 amino acid mismatches with sequences from
M. tuberculosis and induced stronger responses in UK controls compared to leprosy patients. Peptides p6, p10, p18, p20 and p29 have 8, 11, 10, 6 and 11,
respectively, of 17 amino acid mismatches, induced greater responses in leprosy patients than UK controls. These amino acid comparisons were performed
by performing BLASTP searches to M. tuberculosis predicted proteins on the Sanger Centre Database. Sequences with highest scoring segment pairs
were chosen (P-values). Amino acids in bold and underlined are different in the two species and the information in the brackets is the gene name where
known; †denotes signiﬁcant differences between UK > leprosy and *denotes signiﬁcant differences between leprosy > UK as determined by Wilcoxon
rank sum test.Human T cell responses to peptides of M. leprae 45-kD serine-rich antigen 145
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because they had not received any stimulation. Restimulation of
the T cell lines with this peptide p45 resulted in secretion of IFN-
g as shown in Fig. 2.
Further speciﬁcity testing in leprosy and tuberculosis patients
In subsequent experiments, PBMC cultures from a further group
of 16 polar/borderline tuberculoid leprosy patients from Pakistan,
20 non-exposed controls from the United Kingdom, six UK tuber-
culosis patients and 16 Pakistani tuberculosis patients were 
stimulated with selected peptides, PHA, PPD and M. leprae son-
icate. Strong responses were detected to PPD by Pakistani leprosy
patients (100%), UK controls (85%), UK tuberculosis patients
(100%) and Pakistani tuberculosis patients (94%) with mean pro-
duction of 8706pg/ml (range 750–18000pg/ml), 3633pg/ml (range
0–13850pg/ml), 10625pg/ml (range 5300–23600pg/ml) and 10691
pg/ml (range 0–30700pg/ml), respectively. The leprosy patients
responded more strongly (88%) to M. leprae sonicate with a mean
IFN-g production of 2903pg/ml, the UK controls responded least
strongly (50%, mean IFN-g 798pg/ml), UK tuberculosis patients
gave an intermediate response (67% responders) with a mean
IFN-g production of 750pg/ml and Pakistani tuberculosis patients
responded more strongly (63%) with a mean IFN-g production of
1597pg/ml.
The three peptides p18, p19 and p20 were tested with PBMC
from leprosy patients, UK controls and tuberculosis patients to
ascertain the speciﬁcity of these peptides. Peptides p18 and p20
were chosen on the basis that they were recognized most fre-
quently by leprosy patients and not well recognized by UK con-
trols in the preliminary testing (20% responders) and p19 was
included in subsequent testing as it had 15/17 amino acid mis-
matches to a homologue in M. tuberculosis and overlapped p18
and p20. Figure3 shows the percentage of responders to peptides
p18, p19 and p20. The leprosy patients made the strongest
responses to peptides p18, p19 and p20 (50%, 63%, 56% respon-
ders, respectively) with median IFN-g  production levels of 
75pg/ml, 200pg/ml and 225pg/ml. None of these peptides were
well recognized by the UK controls (5%, 0%, 5% responders,
respectively) with ranges of only 0–200pg/ml IFN-g produced in
response to any of the three peptides. The UK tuberculosis
patients’ responses to the peptides were low (17%, 0%, 33%,
respectively). The peptides induced an intermediate response in
the Pakistani tuberculosis patients (44%, 44%, 38%, respec-
tively). The IFN-g responses of individuals to peptides p18, p19
and p20 are shown in Fig. 3 illustrating the variation in recogni-
tion of individual peptides by the different groups. The six UK
tuberculosis patients who came from a variety of ethnic back-
grounds (three African, two UK, one Indian) recognized these
peptides less well compared to the Pakistani tuberculosis patient
group.
HLA type and response to individual peptides
Information on the major HLA-DR alleles expressed by the UK
controls and TT/BT leprosy patients from the initial testing was
available. Therefore, analysis was performed on the correlation
between the presence of predicted HLA-DR binding motifs
(using FINDPATTERNS and SYFPEITHI programs) in the pep-
tides and the HLA types expressed by the subjects tested. In the
case of peptide p45 (which was recognized signiﬁcantly more
strongly by the UK controls than the leprosy patients), there was
a much higher response rate by the controls expressing the HLA-
DR types to which peptide p45 was predicted to bind (for
example, 10 of 11 responders to peptide p45 had DR 1, 4, 7, 1404
or 17): see Table 3. Similarly with peptide p20, 3 of 6 leprosy
patients expressed DR 1, 4, 7, 1404 or 17.
The presence of the correct DR type did not predict that the
individual would make a positive IFN-g response to a particular
peptide. Despite using the HLA predicting programs FINDPAT-
TERNS and SYFPEITHI (http://134·2.96·221/scripts/MHCserver.
dll/home.htm) a high proportion of the peptides seemed to show
promiscuous binding by a range of different HLA alleles. For
example, in the case of peptide p18 predicted to bind to DR 1, 4,
2000
1500
1000
500
0
p45 p18 No stim.
I
F
N
-
g
 
(
p
g
/
m
l
)
Fig.2. The speciﬁcity of a short-term cell line for peptide p45. A short-
term cell line was generated by stimulation of PBMCs with peptide p45
and fed with Lymphocult T and growth medium every 3 or 4 days. On day
14, the line was put onto macrophages presenting peptide p45 or p18 or
unstimulated macrophages and cultured for 3 days. Supernatants were
removed and measured for IFN-g secretion by ELISA. Each dot repre-
sents an individual well containing a cell line, with the means represented
as the horizontal lines. 
Table3. Analysing the presence of predicted HLA-DR binding motifs
and HLA-DR alleles expressed by responder and non responder leprosy
patients and UK controls*
Peptide predicted binding
Number of subjects
alleles and responder status  with alleles without alleles
Leprosy
p18 (DR 1, 4, 7, 17)
Responder 0 2
Non-responder 8 5
p20 (DR1, 4, 7, 1404, 17)
Responder 3 3
Non-responder 6 3
UK
p45 (DR 1, 4, 7, 1404, 17)
Responder 10 1
Non-responder 5 1
*Patients and UK controls were tested for their ability to secrete IFN-
g  in response to individual peptides as described in Materials and methods.
Responders were deﬁned as making ≥100pg of IFN-g per ml. HLA typing
was performed by PCR. Subjects were divided into those expressing the
HLA-DR alleles for which the peptide contained predicted binding motifs
or lacking the correct alleles.146 S. Brahmbhatt et al.
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Peptide p18
Leprosy UK controls UK TB Pakistan TB
1
10
100
1 000
10 000
50% 5% 17% 44%
Peptide p19
Leprosy UK controls UK TB Pakistan TB
1
10
100
1 000
10 000
63% 0% 0% 44%
Peptide p20
Leprosy UK controls UK TB Pakistan TB
1
10
100
1 000
10 000
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Fig.3. IFN-g responses induced by M. leprae 45-kD antigen peptides in
leprosy and tuberculosis patients and UK controls. PBMCs were stimu-
lated for 5 days and IFN-g was measured in the culture supernatants by
ELISA. Concentrations of ≥100pg/ml of IFN-g  were used to deﬁne a 
positive response as shown by the line. N = 16 for TT/BT leprosy patients, 
n = 20 for UK controls, n = 6 for UK tuberculosis patients and n = 16 
for Pakistani tuberculosis patients. Medians are indicated for the leprosy
patients only, as medians for the UK controls and tuberculosis groups were
zero.
7, 1404 and 17, which was recognized signiﬁcantly more strongly
by the TT/BT leprosy patients than the UK controls, responses
were observed for the two donors who lacked these DR motifs.
We are aware that the use of such prediction algorithms for class
II epitopes are of limited value compared to those for class I as
is seen from the data here, individuals without the correct DR
type could also respond to the peptides.
From analysing results of amino acid mismatches (Sanger
Centre) and DR binding (SYFPEITHI database) for the poten-
tially M. leprae speciﬁc peptides p18, p19 and p20, it appears that
the predicted differences between the two species are in the
regions considered important for HLA binding (data not shown).
For example, in peptide p18 the ﬁrst three amino acid are differ-
ent to the equivalent M. tuberculosis sequence (see Table 2b) and
it is amino acids at positions 1 and 3 that are important for binding
to DR 1 and DR4.
DISCUSSION
The aim of this study was to test peptides from the M. leprae 45-
kD antigen (SWISSPROT accession number Q07297) to identify
those that might be M. leprae-speciﬁc, which could be used as a
diagnostic test reagent. Development of such a diagnostic tool
would aid the monitoring of M. leprae transmission, which is not
fully understood and also of disease distribution in endemic areas
in order to target effective public health programmes to these
areas. In a previous study [33] which involved identifying M.
leprae speciﬁc peptides using the genome sequencing data, four
peptides were tested that came from the 45-kD antigen, two 
of which showed some evidence of speciﬁcity. However, these
peptides differed in sequence from those tested here.
An IFN-g response to the 45-kD antigen could be detected in
both UK controls and tuberculoid leprosy patients, although a
slightly higher proportion of the leprosy patients responded. In 
a study in Mexico by MacFarlane et al. [28] 13/14 tuberculoid
leprosy patients responded to the 45-kD antigen. Moreover, IFN-
g  responses to 45-kD antigen were also detected in leprosy
patients (68%) in Nepal [34]. This indicates that the 45-kD
protein may be an immunodominant antigen. However, it also
contains T cell epitopes that are recognized by T cells from UK
non-exposed individuals. In a previous study we used a bioinfor-
matics approach to identify T cell epitopes [33]; however, as we
had the peptides available from a previous serology study we
decided to try the conventional overlapping approach here to
identify T cell epitopes. We therefore used synthetic peptides
spanning the 45-kD antigen, to identify individual peptides con-
taining T cell epitopes recognized preferentially by tuberculoid
leprosy patients.
The completion of the genomes sequencing of M. tuberculo-
sis and M. Leprae [35,36] (http://www.sanger.ac.uk) provided a
unique opportunity to perform amino acid sequence comparisons
of the peptides used in this study. One gene showing homology to
the M. leprae 45-kD antigen sequence is a hypothetical 27-kD
antigen coded by a PPE gene from M. tuberculosis (Rv2108);
using the Sanger Centre database, similarities and mismatches to
the  M. leprae 45-kD peptide sequences were identiﬁed. Some
individual peptides from the M. leprae 45-kD antigen, such as p4
and p21, had very little similarity to corresponding sequences
from M. tuberculosis, but still induced IFN-g responses in UK con-
trols. One explanation for UK controls’ recognition of peptides
that are not similar to those of M. tuberculosis could be that otherHuman T cell responses to peptides of M. leprae 45-kD serine-rich antigen 147
environmental mycobacteria may have similar gene sequences
encoding similar cross-reactive antigens. The comparisons made
so far using the EBI database showed that any homology present
between M. leprae 45-kD and other gene sequences was with gene
sequences of mycobacterial species.
During initial testing a few peptides thought to have poten-
tial as being speciﬁc for M. leprae were also identiﬁed (p18, p20).
Therefore, these peptides together with peptide p19 (overlapping
p18 and p20) were tested with PBMC from another 20 UK donors,
16 TT/BT leprosy patients and 22 tuberculosis patients (from Pak-
istan and the United Kingdom). For the diagnostic test to be effec-
tive in a leprosy endemic country, where tuberculosis is also
endemic, it ought not to generate any response in tuberculosis
patients. However, the tuberculosis patients in Pakistan fre-
quently recognized the selected peptides p18, p19 and p20. This
means these peptides therefore lack speciﬁcity for M. leprae and
would be likely to induce a positive response in subjects exposed
to other mycobacterial species, if formulated as a diagnostic
reagent.
After completion of initial peptide screening it was decided
to conﬁrm further that T cell responses were indeed being gen-
erated to the peptides in vitro (data not shown). Many studies use
overlapping peptides in in vitro assays with the assumption that
the recognition is from T cells, but we decided to conﬁrm that
responses to peptides in our assays were induced by CD3
+T cells
and not CD56
+ cells. Although CD56
+ cells were found to produce
some IFN-g the majority of the cells making IFN-g were CD3
+ T
cells. This was in agreement with ﬁndings by Manandhar et al.,
who demonstrated that depletion of T cells from PBMCs revealed
that CD4
+ T cells were the major but not exclusive contributors
to 24 h IFN-g production through stimulation by MLSA-LAM
[37]. Using puriﬁed CD56
+ NK cells Garcia et al. showed in tuber-
culoid leprosy patients that IFN-g production to M. leprae at 24 h
was dependent on the presence of IL-18, but again IFN-g was pro-
duced in a more sustained manner by CD3
+ T cells [38]. Using
ﬂow cytometry we were able to demonstrate that upon stimula-
tion CD3
+T cells expressing CD45RO
+ memory marker increased
considerably from 1 to 5 days (data not shown). This is similar to
ﬁndings by Picker et al., who demonstrate the existence of in vivo
memory/effector T cells upon stimulation with PMA and Iono-
mycin or SEA/SEB [39]. This study also showed that IFN-g and
IL-4 production is restricted exclusively to memory/effector cells
in freshly isolated PBMCs and DTH skin sites. This is important,
as most diagnostic test rely on the reagent being recognized by
memory T cells that have been previously M. leprae-exposed.
Immunohistochemical techniques have demonstrated that CD3
+
T cells are mainly responsible for IFN-g in tuberculin-induced
DTH skin sites [40]. In order to establish the presence of antigen-
speciﬁc T cells a short-term cell line (STCL) was generated 
to peptide p45 from a donor. This would have the advantage of
clearly ‘amplifying’ the detection of any peptide speciﬁc T cells
present in the assay and demonstrating that PBMC responses
generated to peptides are mainly the result of speciﬁc TCR recog-
nition of peptide rather than the non-speciﬁc stimulation of NK
cells. The STCL data in our study indicated clearly that T cells
were activated and that such T cells were speciﬁc for the autolo-
gous peptide.
When considering the generation of a diagnostic test reagent
it is important to consider the HLA class II restriction of the pep-
tides that are to be incorporated. Ideally, it would be best to
design a cocktail of peptides with the most common HLA-DR
restricted binding motifs that are present in the majority of a 
population. It could also be possible to design a diagnostic test
reagent incorporating promiscuous peptide epitopes that bind to
a variety of HLA grooves but are sequence speciﬁc for M. leprae
alone. We are aware that in using prediction algorithms there are
difﬁculties for class II epitopes due to the degeneracy of these
molecules compared to class I. However, it was interesting to
observe that predicted differences in M. leprae speciﬁc peptides
were in regions considered important for HLA binding.
It was interesting that comparison of amino acid mismatches
between equivalent M. leprae and  M. tuberculosis peptide
sequences did not necessarily provide an indicator of speciﬁcity.
This was clearly observed when even though high amino acid mis-
matches were present between the equivalent peptides of the two
species, positive responses could still be detected in tuberculosis
patients and UK controls. This may result from cross-reactive T
cell responses generated as a result of prior exposure to mycobac-
terial antigens homologous to the M. leprae 45-kD antigen, such
as the hypothetical M. tuberculosis 27-kD. Alternatively, there
may be a protein present in a common environmental mycobac-
terial species such as M. avium. Comparison of the M. leprae
45-kD sequence with contigs of M. avium resulted in a match from
contig 310 using the TIGR database (http://www.tigr.org),
however, as the genome of this species is incomplete it cannot be
assumed to be entirely accurate. This issue will be clariﬁed as the
sequencing of additional mycobacterial species is completed. UK
controls may have very little exposure to M. tuberculosis whereas
within leprosy endemic countries, the prevalence of tuberculosis
is often much higher and such peptides would therefore not be
suitable as a diagnostic tool. With the completion of the M. leprae
genome project [37] it may, however, be possible to identify whole
genes that are present in M. leprae and not in M. tuberculosis, and
which might contain peptide epitopes with greater speciﬁcity for
M. leprae.
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